Serum amyloid A (SAA): A concise review of biology, assay methods and clinical usefulness

Clinical Chemistry and Laboratory Medicine

Volumn 37, Issue 4, 1999, Pages 381-388

  Yamada, Toshiyuki ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Assay method; C reactive protein; Clinical significance; Inflammation; Serum amyloid A

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CYTOKINE; ISOPROTEIN; SERUM AMYLOID A;

BIOLOGY; CLINICAL LABORATORY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INFLAMMATION; KIDNEY ALLOGRAFT REJECTION; MULTIGENE FAMILY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; PROTEIN FAMILY; PROTEIN URINE LEVEL; REVIEW; VIRUS INFECTION;

EID: 0032918632     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.1999.063     Document Type: Review

References (104)

1. Benditt EP, Eriksen M, Hermodsen MA, Ericsson LH. The major proteins of human and monkey amyloid substance: common properties including unusual N-terminal amino acid sequences. FEBS Lett 1971; 19:169-73.
2. Levin M, Pras M, Franklin EC. Immunologic studies of the major nonimmunoglobulin protein of the amyloid. Identification and partial characterization of a related serum component. J Exp Med 1973; 138:373-80.
3. Husby G, Natvig JB. A serum component related to nonimmunoglobulin amyloid protein AS, a possible precursor of the fibrils. J Clin Invest 1974; 53:1054-61.
4. McAdam KP, Anders-RF, Smith SR, Russell DA, Price MA. Association of amyloidosis with erythema nodosum leprosum reactions and recurrent neutrophil leucocytosis in leprosy. Lancet 1975; 27:572-3.
5. Benditt EP, Eriksen N. Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc Natl Acad Sci USA 1977; 74:4025-8.
6. Benson MD. Amyloidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle DV, editors. The metabolic basis of inherited disease. 7ed. New York: McGraw-Hill, 1995:4159-91.
7. Husby G, Marhaug G, Dowton B, Sletten K, Sipe JD. Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis, Amyloid Int J Exp Clin Invest 1994; 1:119-37.
8. Malle E, deBeer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996; 26:427-35.
9. Malle E, Steinmetz A, Raynes JG. Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis 1993; 102:131-46.
10. Yamada T, Nomata Y, Sugita O, Okada M. A rapid method for measuring serum amyloid A protein by latex agglutination nephelometric immunoassay. Ann Clin Biochem 1993; 30:72-6.
11. Dwulet FE, Benson MD. Amino acid structures of multiple forms of amyloid related serum protein SAA from a single individual. Biochemistry 1988; 27:1677-82.
12. Betts JC, Edbrooke MR, Thakker RV, Woo P. The human acute-phase serum amyloid A gene family: structure, evolution and expression in hepatoma cells. Scand J Immunol 1991; 34:471-82.
13. Whitehead AS, de Beer MC, Rits M, Lelias JM, Lane WS, de Beer FC. Identification of novel members of serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. J Biol Chem 1992; 267:3862-7.
14. Kluve-Becherman B, Drumm ML, Benson MD. Nonexpression of the serum amyloid A three (SAA3) gene. DNA Cell Biol 1991; 10:651-61.
15. Baba S, Takahashi T, Kasama T, Fujie M, Shirasawa H. A novel polymorphism of human serum amyloid A protein, SAA1g, is characterized by alanines at both residuess 52 and 57. Arch Biochem Biophys 1993; 303:361-6.
16. Sipe JD. Serum amyloid A protein classification: a preliminary report of a subcommittee of the International Society of Amyloidosis. Amyloid. Int J Exp Clin Invest 1995; 2:69-70.
17. Baba S, Masago SA, Takahashi T, Kasama T, Sugimura H, Tsugane S, et al. A novel alleic variant of serum amyloid A. SAA1g: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic amyloidosis. Hum Mol Genet 1995; 4:1083-7.
18. Faulkes D, Betts J, Woo P. Alleles of human SAA1. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID, editors. Amyloid and amyloidosis. New York: Parthenon Publishing, 1993:73-4.
19. Yamada T, Itoh Y, Itoh K. Analysis of serum amyloid A1 alleles by PCR-RFLP. Rinsho Byori (in Japanese and English abstract) 1998; 47:53-5.
20. Hazenberg BPC, Limburg PC, Bijzet J, van Rijswijk MH. SAA isoform patterns in patients with and without AA-amyloidosis. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID, editors. Amyloid and amyloidosis. New York: Parthenon Publishing, 1993:90-2.
21. Yamada T, Okuda Y, Itoh Y. The frequency of serum amyloid A2 alleles in the Japanese population. Amyloid Int J Clin Exp Invest 1998; 5:208-11.
22. Westermark GT, Engström U, Westermark P. The N-terminal segment of protein AA determines its fibrillogenic property. Biochem Biophys Res Commun 1992; 182:27-33.
23. Patel H, Bramall J, Waters H, de Beer MC, Woo P. Expression of recombinant human serum amyloid A in mammalian cells and demonstration of the region necessary for high-density lipoprotein binding and amyloid fibril formation by site-directed mutagenesis. Biochem J 1996; 318:1041-9.
24. de Beer MC, Yuan T, Kindy MS, Asztalos BF, Roheim PS, de Beer FC. Characterization of constitutive human serum amyloid A protein (SAA4) as an apolipoprotein. J Lipid Res 1995; 36:526-34.
25. Yamada T, Miida T, Itoh Y, Kawai T, Benson MD. Characterization of serum amyloid A4 as a plasma apolipoprotein. Clin Chim Acta 1996; 251:105-12.
26. Kushner I. The acute phase response: an overview. Methods Enzymol 1988; 163:373-83.
27. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15:74-80.
28. Edbrooke MR, Foldi J, Cheshire JK, Li F, Faulkes DJ, Woo P. Constitutive and NF-κB-like proteins in the regulation of the serum amyloid A gene by interleukin 1. Cytokine 1993; 3:380-8.
29. Meek RL, Benditt EP. Amyloid A gene family expression in different mouse tissues. J Exp Med 1986; 164:2006-17.
30. Kluve-Beckerman B, Yamada T, Hardwick J, Liepnieks JJ, Benson MD. Differential plasma clearance of murine acute-phase amyloid A proteins SAA1 and SAA2. Biochem J 1997; 322:663-9.
31. SAA) by murine macrophages in vitro. A light and electronmicroscopic investigation. Amyloid Int J Exp Clin Invest 1997; 4:259-73.
32. Lavie G, Zucker-Franklin D, Franklin EC. Degradation of serum amyloid A protein by surface-associated enzymes of human blood monocytes. J Exp Med 1978; 148:1020-31.
33. Bausserman LL, Saritelli AL, Van Zuiden P, Gollaher CJ, Herbert PN. Degradation of serum amyloid A by isolated perfused rat liver. J Biol Chem 1987; 262:1583-9.
34. Yamada T, Liepnieks JJ, Kluve-Beckerman B, Benson MD. Cathepsin B generates the most common form of amyloid A (76 residues) as a degradation product from serum amyloid A. Scand J Immunol 1995; 41:94-7.
35. Aldo-Benson MA, Benson MD. SAA suppression of immune response in vitro: evidence for an effect on T cell-macrophage interaction. J Immunol 1982; 126:2390-2.
36. Zimlichman S, Danon A, Nathan I, Mozes G, Shaikin-Kestenbaum R. Serum amyloid A, an acute phase protein, inhibits platelet activation. J Lab Clin Invest 1990; 116:180-6.
37. Linke RP, Bock V, Valet G, Rothe G. Inhibition of the oxidative burst response of N-formyl peptide-stimulated neutrophils by serum amyloid-A protein. Biochem Biophys Res Commun 1991; 176:1100-5.
38. Mitchell TI, Coon CI, Brinckerhoff CE. Serum amyloid A (SAA3) produced by rabbit synovial fibroblasts treated with phorbol esters or interleukin 1 induces synthesis of collagenase and is neutralized with specific antiserum. J Clin Invest 1991; 87:1177-85.
39. Badolato R, Wang JM, Murphy WJ, Lloyd AR, Michiel DF, Bausserman LL, et al. Serum amyloid A is a chemoattractant induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 1994; 180:201-10.
40. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, Mcintype TM, Prescott SM, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. J Clin Invest 1995; 96:2758-67.
41. Migita K, Kawabe Y, Tominaga M, Origuchi T, Aoyagi T, Eguchi K. Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts. Lab Invest 1988; 78:536-9.
42. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, deBeer FC. Serum amyloid A-containing human high density lipoprotein 3: density, size and apolipoprotein composition. J Biol Chem 1986; 261:9644-51.
43. Clifton PM, Mackinnon AM, Barter PJ. Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J Lipid Res 1985; 26:1389-98.
44. Kisilevsky R, Subrahmanyan L. Serum amyloid A changes high density lipoproteins cellular affinity. Lab Invest 1992; 66:778-85.
45. Steinmetz A, Hocke G, Saile R, Puchois P, Fruchart J-C. Influence of serum amyloid A on cholesterol esterification in human plasma. Biochim Biophys Acta 1989; 1006:173-8.
46. Meek RL, Urieli-Shoval S, Benditt EP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells. Implications for serum amyloid A function. Proc Natl Acad Sci USA 1994; 91:3186-90.
47. Kumon Y, Sipe JD, Brinckerhoff CE, Schreiber BM. Regulation of extrahepatic apolipoprotein serum amyloid A (ApoSAA) gene expression by interleukin-1 alpha alone: synthesis and secretion of ApoSAA by cultured aortic smooth muscle cells. Scand J Immunol 1997; 46:284-91.
48. Yamada T, Kakihara T, Kamishima T, Fukuda T, Kawai T. Both acute phase and constitutive serum amyloid A are present in the atherosclerotic lesions. Pathol Int 1996; 46:797-800.
49. Yamada T, Miida T, Yamaguchi T, Itoh Y. Effect of serum amyloid A on cellular affinity of low density lipoprotein. Eur J Clin Chem Clin Biochem 1997; 35:421-6.
50. Oram JF. Does serum amyloid A mobilize cholesterol from macrophages during inflammation? Amyloid Int J Exp Clin Invest 1996; 3:290-3.
51. Kobayashi H, Tada S, Fuchigami T, Okuda Y, Takasugi K, Matsumoto T, et al. Amyloidosis in rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy. Br J Rheumatol 1996; 35:44-9.
52. Okuda Y, Takasugi K, Oyama T, Oyama H, Nanba S, Miyamoto T. Intractable diarrhoea associated with secondary amyloidosis in rheumatoid arthritis. Ann Rheum Dis 1997; 56:535-41.
53. Laakso M, Mutru O, Isomaki HA, Koota K. Mortality from amyloidosis and renal diseases in patients with rheumatoid arthritis. Ann Rheum Dis 1986; 45:663-7.
54. Fuks A, Zucker-Franklin D. Impaired Kupffer cell function precedes development of secondary amyloidosis. J Exp Med 1985; 161:1013-28.
55. Yamada T, Liepnieks JJ, Benson MD, Kluve-Beckerman B. Accelerated amyloid deposition in mice treated with the aspartic protease inhibitor, pepstatin. J Immunol 1996; 157:901-7.
56. Kisilevsky R. Heparan sulfate proteoglycans in amyloidogenesis: an epiphenomenon, a unique factor, or the tip of a more fundamental process. Lab Invest 1990; 63:589-91.
57. Yamada T, Kluve-Beckerman B, Liepnieks JJ, Benson MD. Fibril formation from recombinant human serum amyloid A. Biochim Biophys Acta 1994; 1226:323-9.
58. Rosenthal CJ, Franklin EC. Variation with age and disease of an amyloid A protein-related serum component. J Clin Invest 1975; 55:746-53.
59. Yamada T, Hirano N, Kuroda T, Okuda Y, Itoh Y. Generation and characterization of rat monoclonal antibodies against human serum amyloid A. Scand J Immunol 1997; 46:175-9.
60. Godenir NL, Jeenah MS, Coetzee GA, van der Westhuyzen DR, Strachan AG, de Beer FC. Standardization of the quantitation of serum amyloid A protein (SAA) in human serum. J Immunol Methods 1985; 83:217-25.
61. Poole S, Walker D, Das REG, Gallimore JR, Pepys MB. The first international standard for serum amyloid A protein (SAA). Evaluation in an international collaborative study. J Immunol Methods 1988; 214:1-10.
62. McCormack CC, Hobson AH, Doyle S, Jackson J, Kilty C, Whitehead AS. Generation of soluble recombinant human acute phase serum amyloid A2 (A-SAA2) protein and its use in development of a A-SAA specific ELISA. J Immunol Methods 1996; 198:101-10.
63. Wada A, Yamada T, Kubota N. Measurement of serum amyloid A by commonly used automated analyzers. Ann Clin Biochem 1997; 34:569-70.
64. Hocke G, Ebel H, Bittner K, Maller T, Kaffarnik H, Steinmetz A. A rapid laser immunonephelometric assay for serum amyloid A (SAA) and its application to the diagnosis of kidney allograft rejection. Klin Wochenschr 1989; 67:447-51.
65. Wilkins J, Gallimore JR, Tennent GA, Hawkins PN, Limburg PC, van Rijswijk MH, et al. Rapid automated enzyme immunoassay of serum amyloid A. Clin Chem 1994; 40: 1284-90.
66. Sipe JD, Gonnerman WA, Loose LD, Knapschaefer G, Xie WJ, Franzblau C. Direct binding enzyme-linked immunosorbent assay (ELISA) for serum amyloid A (SAA). J Immunol Methods 1989; 125:125-35.
67. Wada A, Yamada T, Itoh Y, Itoh K. Development of highly sensitive enzyme-linked immunosorbent assay for serum amyloid A and application for clearance study. Rinsho Byori (in Japansese and English abstract) 1998; 46:1252-7.
68. Urieli-Shoval S, Meek RL, Hanson RH, Eriksen N, Benditt EP. Human serum amyloid A genes are expressed in monocyte/macrophage cell line. Am J Pathol 1994; 145: 650-60.
69. Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 1994; 15:81-8.
70. Rosenson RDS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 1993; 22:933-40.
71. Yamada T, Uchiyama K, Yakata M, Gejyo F. Sandwich enzyme immunoassay for serum amyloid A protein (SAA). Clin Chim Acta 1989; 178:169-76.
72. Mozes MD, Friedman N. Serum amyloid A: an extremely sensitive marker for intensity of tissue damage in trauma patients and indicator of acute phase response in various diseases. J Trauma 1989; 29:71-4.
73. Marhaug G, Harklau L, Olsen B, Husby G, Husebekk A, Wang H. Serum amyloid A protein in acute myocardial infarction. Acta Med Scand 1986; 220:303-6.
74. Marhaug G, Permin H, Husby G. Amyloid-related serum amyloid protein (SAA) as an indicator of lung infection in cystic fibrosis. Acta Paediatr Scand 1983; 72:861-6.
75. Shainkin-Kestenbaum R, Winikoff Y, Cristal N. Serum amyloid A concentration during the coure of acute ischaemic heart disease. J Clin Pathol 1986; 39:635-7.
76. Chambers RE, Stross P, Barry RE, Whicher JT. Serum amyloid A protein compared with C-reactive protein, alpha 1-antichymotrypsin and alpha 1-acid glycoprotein as a monitor of inflammatory bowel disease. Eur J Clin Invest 1987; 17:460-7.
77. Benson MD, Cohen AS. Serum amyloid A protein in amyloidosis, rheumatic and neoplastic diseases. Arthritis Rheum 1979; 22:36-42.
78. de Beer FC, Fagan EA, Hugher GRV, Mallya RK, Lanham JG, Pepys MB. Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982; ii: 231-3.
79. Shainkin-Kestenbaum R, Zimlichman S, Winikoff Y, Pras M, Chaimovitz C, Sarov I. Serum amyloid A (SAA) in viral infection: rubella, measles and subacute sclerosing panencephalitis (SSPE). Clin Exp immunol 1982; 50:503-6.
80. Sarcov I, Shainkin-Kestenbaum R, Zimlichman S, Winikoff Y, Chaimovitz C, Pras M. Serum amyloid A levels in patients with infections due to cytomegalovirus, varicellazoster virus, and herpes simplex virus. J Infect Dis 1982; 146:443.
81. Weinstein PS, Skinner M, Sipe JD, Lokich JJ, Zahmcheck N, Cohen AS. Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol 1984; 19:193-8.
82. Biran H, Friedman N, Neumann L, Pras M, Shainkin-Kestenbaum R. Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 1986; 39:794-7.
83. Casl MT, Coen D, Simic D. Serum amyloid A protein in the prediction of postburn complications and fatal outcome in patients with severe burns. Eur J Clin Chem Clin Biochem 1996; 34:31-5.
84. Miwata H, Yamada T, Okada M, Kudo T, Kimura H, Morishima T. Serum amyloid A protein in acute viral infections. Arch Dis Child 1993; 68:210-4.
85. Nakayama T, Shinoda S, Urano T, Yamada T, Okada M. Monitoring both serum amyloid A and C-reactice protein as inflammatory markers in infectious diseases. Clin Chem 1993; 39:293-7.
86. Whicher JT, Chambers RE, Higginson J, Nashef L, Higgins PG. Acute phase response of serum amyloid A protein and C-reactive protein to the common cold and influenza. J Clin Pathol 1985; 38:312-6.
87. Hogarth MB, Gallimore R, Savage P, Palmer AJ, Starr JM, Bulpitt CJ, et al. Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient. Age Ageing 1997; 26:153-8.
88. Lozanski G, Jiang SL, Samols D, Kushner I. C-reactive protein and serum amyloid A mRNA stability following induction by cytokines. Cytokine 1996; 8:534-40.
89. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Eng J Med 1994; 331:417-24.
90. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349:462-6.
91. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97:425-8.
92. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. J Am Med Assoc 1998; 279:1477-82.
93. Maury CPJ, Teppo AM, Eklund B, Ahonen J. Serum amyloid A protein: a sensitive indicator of renal allograft rejection in humans. Transplantation 1983; 36: 501-4.
94. 2-microglobulin as markers of renal allograft rejection. Clin Nephrol 1984; 22:284-92.
95. Maury CPJ. Comparative study of serum amyloid A protein and C-reactive protein in disease. Clin Sci 1985; 68: 233-8.
96. Hartmann A, Eide TC, Fauchald P, Bentdal O, Herbert J, Gallimore JR, et al. Serum amyloid A protein is a clinically useful indicator of acute renal allograft rejection. Nephrol Dial Transplant 1997; 12:161-6.
97. Ogata F, Kohoda Y, Suzuki M, Hirasawa Y. High levels of serum amyloid A persist for a long time after kidney transplantation. Nephron 1990; 53:216-7.
98. Cohen DJ, Benvenisty AI, Meyer E, Cianci J, Kelly J, Hardy MA. Failure of C-reactive protein concentration to rise with acute rejection in cyclosporine-treated renal allograft recipients. Transplant Proc 1986; 18:713-5.
99. Smith JW, Colombo JL, McDonald TL. Comparison of serum amyloid A and C-reactive protein as indicators of lung inflammation in corticosteroid treated and non-corticosteroid treated cystic fibrosis patients. J Clin Lab Anal 1992; 6:219-24.
100. Shimetani N, Ichikawa K, Hachimura K, Tanaka T, Ohtani S, Kanon Y, et al. Variations of serum amyloid A protein and interleukin-6 in patients with low concentration of serum C-reactive protein. Rinsho-Byori (In Japanese and English abstract) 1996; 44:669-75.
101. Feussner G, Stech C, Dobmeyer J, Schaefer H, Otto G, Ziegler R. Serum amyloid A protein (SAA): a marker for liver allograft rejection in humans. Clin Invest 1994; 72: 1007-11.
102. Uguccioni M, Meliconi R, Lalli E, Nesci S, Delfini C, Lucarelli G, et al. Serum amyloid A protein concentrations in bone marrow transplantation for β thalassaemia. J Clin Pathol 1992; 45:348-51.
103. Niederau C, Backmerhoff F, Schumacher B, Niederau C. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology 1997; 44:90-107.
104. Beach CM, de Beer MC, Sipe JD, Loose LD, de Beer FC. Human serum amyloid A protein. Complete amino acid sequence of a new variant. Biochem J 1992; 282:615-20.